BioRestorative Therapies (BioRestorative Therapies) Change In Working Capital : $0.52 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is BioRestorative Therapies Change In Working Capital?

BioRestorative Therapies's change in working capital for the quarter that ended in Dec. 2023 was $0.13 Mil.

BioRestorative Therapies's change in working capital for the fiscal year that ended in Dec. 2023 was $0.52 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

BioRestorative Therapies Change In Working Capital Historical Data

The historical data trend for BioRestorative Therapies's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioRestorative Therapies Change In Working Capital Chart

BioRestorative Therapies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

0.54

0.57

0.33

0.01

0.52

BioRestorative Therapies Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Working Capital	Get a 7-Day Free Trial															-0.34	-0.04	0.28	0.14	0.13

BioRestorative Therapies Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.52 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

BioRestorative Therapies Change In Working Capital Related Terms

Thank you for viewing the detailed overview of BioRestorative Therapies's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

BioRestorative Therapies (BioRestorative Therapies) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioRestorative Therapies Inc (NAS:BRTX) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

9OF:Germany

Address

40 Marcus Drive, Suite One, Melville, NY, USA, 11747

Website

https://www.biorestorative.com

BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.

Executives

Dale Broadrick	10 percent owner	3003 BRICK CHURCH PIKE, NASHVILLE TN 37207
Lance Alstodt	director, 10 percent owner, officer: President, CEO, COB	BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE 1, MELVILLE NY 11747
Francisco Silva	director, 10 percent owner, officer: VP of Research and Development	STEM CELL ASSURANCE, INC., 555 HERITAGE DRIVE, JUPITER FL 33458
Robert Eugene Kristal	officer: Chief Financial Officer	4719 COLE AVENUE, DALLAS TX 75205
Patrick F. Williams	director	C/O ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD, SUITE 100, PLEASANTON CA 94588
David A Rosa	director	10901 RED CIRCLE DRIVE, SUITE 150, MINNETONKA MN 55343
Nickolay V. Kukekov	director	4524 WESTWAY AVE, DALLAS TX 75205
Mark Weinreb	director, 10 percent owner, officer: CEO and Chairman of the Board	STEM CELL ASSURANCE, INC., 555 HERITAGE DRIVE, JUPITER FL 33458
Paul Jude Tonna	director	69 CHICHESTER ROAD, HUNTINGTON NY 11743
A. Jeffrey Radov	director	8 WALWORTH AVENUE, SCARSDALE NY 10583
Robert Paccasassi	officer: VP, Quality and Compliance	C/O BIORESTORATIVE THERAPIES, INC., 40 MARCUS DRIVE, SUITE 1, MELVILLE NY 11747
Robert B Catell	director	62 OSBORNE ROAD, GARDEN CITY NY 11530
Adam D. Bergstein	officer: SVP, Planning and Business Dev	167 HAZEL AVENUE, GLENCOE IL 60022
John M Desmarais	director	230 PARK AVENUE, NEW YORK NY 10169
Westbury Trust	10 percent owner	VICTORIA HALL, 11 VICTORIA STREET, P.O. BOX HM 1065, HAMILTON D0 00000